About US
Contact us
-
Is once-skeptical J&J coming around on pharma's breakup craze?SAN FRANCISCO--Johnson & Johnson ($JNJ) has been pretty quiet over the past couple of years as it's watched its Big Pharma peers slim down like there's no tomorrow. But now, it seems the pharma gi2015/1/13
-
Bayer shuffles agency assignments to fold in Merck OTC brandsBayer, gunning for the global consumer health lead, said over the summer that it's intent on keeping all the OTC brands it picked up in its $14.2 billion deal for Merck's ($MRK) unit. But in order for2015/1/12
-
Roche builds CLL case for Gazyva in two-horse race with GSKRoche ($RHHBY) wonFDAapproval for a supplemental license application of its chronic lymphocytic leukemia (CLL) drugGazyva, strengthening its case over rival GlaxoSmithKline ($GSK) and adding some ammo2015/1/12
-
FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain managementHospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administrat2015/1/10
-
Tikcro enters into research and license agreement with YedaTikcro Technologies Ltd. (OTC PK: TIKRF) today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the W2015/1/9
-
FDA approves Myriad’s BRACAnalysis CDx for use with ovarian cancer drugBRACAnalysis CDx is First and Only FDA-Approved Test to Assess BRCA Status Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that it has received approval from the U.S. Food and Drug Administratio2015/1/9
-
CFDA Vice Minister Wu Zhen meets German Ambassador to ChinaOn December 22, 2014, Wu Zhen, Vice Minister of China Food and Drug Administration (CFDA), met with the delegation led by German Ambassador to China Michael Clauss. Both sides reviewed the cooperation2015/1/8
-
FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's diseaseActavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixe2015/1/7
-
Newron, Zambon announce re-submission of safinamide NDA to FDANewron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmac2014/12/30
-
Catalent Biomanufacturing Center of Excellence, Madison, Wisconsin, United States of AmericaCatalent Pharma Solutions opened a state-of-the-art bio-manufacturing centre of excellence in Madison, Wisconsin, US, in April 2013. Following the inauguration, Catalent relocated its operations and 82014/12/30